Drugs / Dexamethasone palmitate emulsion
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04488315 | Oct 2022 → Sep 2023 | neuropathy, painful | Beijing Tiantan Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dexamethasone palmitate emulsion | “Dexamethasone palmitate emulsion (D-PAL) is a pro-drug incorporating dexamethasone into lipid microspheres with greater anti-inflammatory activity and fewer side effects than...” PMID 36510271 ↗ Dec 2022 |
| Known as | D-PAL | “Dexamethasone palmitate emulsion (D-PAL) is a pro-drug incorporating dexamethasone into lipid microspheres with greater anti-inflammatory activity and fewer side effects than...” PMID 36510271 ↗ Dec 2022 |
| Route | Other | “pre-emptive scalp infiltration with ropivacaine plus D-PAL emulsion” PMID 36510271 ↗ Dec 2022 |